Trispecific Antibodies for Cancer Immunotherapy.
Sign Up to like & getrecommendations! Published in 2023 at "Immunology"
DOI: 10.1111/imm.13636
Abstract: Despite the clinical success of monoclonal and bispecific antibodies, there are still limitations in the therapeutic effect of malignant tumors, such as low response rate, treatment resistance, etc., inspiring the exploration of trispecific antibodies (TsAbs).… read more here.
Keywords: immunology; trispecific antibodies; cancer immunotherapy; antibodies cancer ... See more keywords
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Theranostics"
DOI: 10.7150/thno.81494
Abstract: Despite the clinical success of the first bispecific antibody approved by the FDA against B cell malignancies (blinatumomab), many obstacles remain such as dosing, treatment resistance, and modest efficacy in solid tumors. To overcome these… read more here.
Keywords: multispecific antibodies; three crowd; crowd trispecific; trispecific antibodies ... See more keywords